INTS (intensitytherapeutics.com) Long-Term Debt

Intensity Therapeutics is implementing a targeted drug injection method into tumors to reduce therapy toxicity. This price chart demonstrates the company's metrics, where long-term debt stands at 0.00. The business seeks dominance in the immunotherapy sector through the development of the INT230-6 system. The current priority is the expansion of clinical trials for breast cancer and solid tumor drugs within the US market.

Investors must evaluate the capital structure stability of Intensity Therapeutics (INTS) by analyzing the total volume of long-term debt maturing in over a year designated for financing capital expenditures. The trend in the issuer's long-term liabilities reflects the business's degree of reliance on external borrowing while developing its proprietary intratumoral therapy system, which creates a technological barrier for competitors and defines the long-term investment strategy.